SIR 2024
Interventional Oncology
Hiroki Satomura, MD (he/him/his)
Clinical Fellow
Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Japan
Financial relationships: Full list of relationships is listed on the CME information page.
Yasushi Kimura, MD, PhD (he/him/his)
Project Assistant Professor
Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
Kosuke Tomotake, MD
Clinical Fellow
Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
Hiroki Yano, MD
Clinical Fellow
Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
Yuji Koretsune, MD
Clinical Fellow
Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
Daisuke Katayama, MD, PhD
Assistant Professor
Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
Kaishu Tanaka, MD, PhD
Assistant Professor
Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
yusuke ono, n/a
Assistant Professor
Department of Diagnostic and Interventional Radiology Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
Hiroki Higashihara, n/a
associate professor
Department of Diagnostic and Interventional Radiology Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
noriyuki tomiyama, n/a
professor
Department of Diagnostic and Interventional Radiology Osaka University Graduate School of Medicine, Japan
Disclosure information not submitted.
This study aimed to generate and characterize a novel lipiodol pickering emulsion incorporating anti PD-L1 antibodies in vitro.
Materials and Methods:
Lipiodol pickling emulsions were synthesized by mixing Lipiodol (Guerbet Japan, Tokyo, Japan: oil phase) with Poly(lactic-co-glycolic acid)(PLGA) nanoparticles and anti PD-L1 antibodies (Genentech, Inc., Oceanside, CA) distributed in pure water (aqueous phase). PLGA nanoparticles (mean: 168nm) were provided by Lilac Pharma Inc. (Sapporo, Japan). To create water-in-oil pickering emulsions, two parts of the oil phase were mixed with one part of the aqueous phase with three-way stopcock by repetitive pumping (20 times). To ascertain the encapsulation of water phase by PLGA nanoparticles, we employed PLGA nanoparticles stained with Rhodamine B (Nacalai Tesque inc., Kyoto, Japan) and anti PD-L1 antibodies labeled with Alexa Fluor 488 for imaging. After generating the lipiodol pickling emulsions, the droplet was visualized by a confocal laser microscope (LSM710, Carl Zeiss Co., Ltd., Tokyo, Japan). To characterize the sustained release of anti PD-L1 antibodies from the pickering emulsion, a drug release test was conducted. The lipiodol pickering emulsion was dropped into normal saline and maintained at 37℃ with continuous shaking. The release of anti PD-L1 antibodies was quantified using bicinchoninic acid (BCA) assay at 1 hour, 5 hours, 1 day, 3 days, 7 days, and 14 days. To assess the droplet size of the pickering emulsions, light microscope (BZ-X800L, Keyence, Osaka, Japan) was employed. Normal lipiodol emulsion served as the control in the aforementioned experiments.
Results:
Confocal laser microscopy revealed that anti PD-L1 antibodies were effectively encapsulated by PLGA nanoparticles located at the interface between the aqueous and the oil phase. The drug release test showed that the protein concentrations averaged 5.13μg/ml at 1 hour, 9.79μg/ml at 5 hours, 17.5μg/ml at 1 day, 31.8μg/ml at 3 days, 49.5μg/ml at 7 days, and 82.3μg/ml at 14 days, respectively. The release rate was significantly slower than that of the normal lipiodol emulsion. The mean droplet size was 31.3μm at 24 hours which was significantly smaller than normal lipiodol emulsion.
Conclusion:
The lipiodol pickering emulsion effectively encapsulated and continuously released anti PD-L1 antibodies, holding great promise for therapeutic applications.